ArticleInternational journal of molecular sciences2020
Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 3 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- COVID-19 clinical manifestations and treatment strategies among solid-organ recipients: A systematic review of cases.Transplant infectious disease : an official journal of the Transplantation Society · 2020Pooled it
- Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2020Pooled it
- Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.The Cochrane database of systematic reviews · 2020Pooled it
- A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- In silico studies to understand the interactions of flavonoid inhibitor with nsp12-RNA dependent RNA polymerase of SARS-CoV-2 and its homologs.Biochemistry and biophysics reports · 2025Article
- Monitoring of immunoglobulin treatment compliance of patients with an inborn error of immunity during the pandemic period.BMC immunology · 2025Article
- Effects of the COVID-19 Pandemic on Dairy Consumption Trends: An Empirical Investigation of Accounting Data in China.Foods (Basel, Switzerland) · 2024Article
- Evaluation of the Efficacy and Safety of Intravenous Immunoglobulin (IVIG) in Moderate-to-Severe Hospitalized COVID-19 Patients: A Randomized, Open-Label Parallel-Group Study.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Article
- Symmetrical peripheral gangrene: potential mechanisms and therapeutic approaches in severe COVID-19.Frontiers in cardiovascular medicine · 2023Review
- Article
- Review
- Advanced Molecular and Immunological Diagnostic Methods to Detect SARS-CoV-2 Infection.Microorganisms · 2022Review
- An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).International immunopharmacology · 2022Review
- Stem cell therapy for COVID-19 pneumonia.Molecular biomedicine · 2022Review
- Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm.Interface focus · 2022Review
- The striking mimics between COVID-19 and malaria: A review.Frontiers in immunology · 2022Review
- Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality.International reviews of immunology · 2022Article
- Hyper-Immune Bovine Milk as an Immunological and Nutritional Supplement for COVID-19.Frontiers in nutrition · 2022Article
- The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines.Biochemical Society transactions · 2021Review
- Current trends in diagnosis and treatment strategies of COVID-19 infection.Environmental science and pollution research international · 2021Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains that cross the species barrier and infect humans. At the present, there is no single specific vaccine or efficient antiviral therapy against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment reduces inflammation of intestinal epithelial cells and eliminates overgrowth of the opportunistic human fungal pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.